N8-GP: A new extended half-life recombinant factor VIII product for hemophilia A

被引：2
|
作者：
Chowdary, Pratima [1 ]
机构：
[1] Royal Free Hosp, Katharine Dormandy Haemophilia & Thrombosis Ctr, Pond St, London NW3 2QG, England
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2020年 / 18卷
关键词：
D O I：
10.1111/jth.14966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [1] Half-life extended factor VIII for the treatment of hemophilia A
    Tiede, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S176 - S179
  • [2] Coagulopathy Hemophilia A: recombinant Factor VIII with long Half-life
    Weber, Christian
    TRANSFUSIONSMEDIZIN, 2014, 4 (02) : 63 - 63
  • [3] Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
    Kearney, Susan
    Raffini, Leslie J.
    Pham, Tan P.
    Lee, Xin Ying
    von Mackensen, Sylvia
    Landorph, Andrea
    Takedani, Hideyuki
    Oldenburg, Johannes
    PATIENT PREFERENCE AND ADHERENCE, 2019, 13 : 497 - 513
  • [4] Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement
    Ozelo, Margareth Castro
    Antunes, Sandra Vallin
    Villaca, Paula Ribeiro
    Oliveira, Luciana Correa
    Pinto, Ieda Solange
    Lorenzato, Claudia Santos
    Prezotti, Alessandra Nunes Loureiro
    Picoli, Renato Mantelli
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 (01) : 36 - 41
  • [5] PHARMACOKINETIC DRUG EVALUATION OF STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII IN PATIENTS WITH HEMOPHILIA A
    Lopez-Jaime, F-J
    Perez-Raya, M.
    Doblas-Marquez, A.
    Martin-Tellez, S.
    Mena-Santano, A-M
    Munoz-Lopez, F-D
    HAEMOPHILIA, 2021, 27 : 107 - 107
  • [6] Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
    Koc, Basak
    Ozturk, Metin Ishak
    Zulfikar, Bulent
    TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (01) : 62 - 63
  • [7] Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
    Berntorp, Erik
    Andersson, Nadine G.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2016, 42 (05): : 518 - 525
  • [8] Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A
    Mannucci, Pier Mannuccio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (03) : 303 - 309
  • [9] EXTENDED HALF-LIFE (EHL) RECOMBINANT FACTOR VIII (RFVIII) FOR THE TREATMENT OF HEMOPHILIA A IN ITALY: COST OF TREATMENT COMPARISON
    Demma, F.
    Di Martino, G.
    VALUE IN HEALTH, 2021, 24 : S203 - S203
  • [10] COST OF STANDARD HALF-LIFE VERSUS EXTENDED HALF-LIFE RECOMBINANT COAGULATION FACTOR VIII IN PATIENTS WITH HEMOPHILIA A IN SPAIN: RESULTS FROM A PROBABILISTIC MODEL
    Peral, C.
    Kim, H. K.
    Rubio-Rodriguez, D.
    Rubio Terres, C.
    VALUE IN HEALTH, 2019, 22 : S421 - S422
12345